Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases.
Blog Post
International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.
Blog Post
AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.
showing 1-10 of 1276
AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases.
International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.
AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.
Prevention Option:
Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded hepatitis B vaccine trial in Guinea-Bissau, and proposed changes to NIH’s scientific peer-review process raise new questions about transparency and political influence over research funding.
The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be complete by November 30, 2027, when their current funding is set to expire.” This potentially devastating development comes as new questions emerge about how billions in US foreign assistance funding were spent, and details on the impacts of an end of US health assistance to Zimbabwe emerge. Also, a new candidate for WHO leadership and growing civil society calls to protect UNAIDS.
Advocacy has always been the heartbeat of progress in the fight against HIV/AIDS. Now, more than ever, it is especially needed to ensure that innovation translates into real choices, equitable access and meaningful impact. In this issue, we highlight the power of coalition advocacy – from advocates working in partnership to shape research agendas and oppose policies that threaten progress, to ensuring communities have a voice in AI development and use, to the lessons learned from sustained, coalition-based advocacy that will shape what comes next.
The power and leadership of advocates were on full display at AIDS 2026. Following global funding cuts and concerns about de-prioritization of communities and civil society, advocates brought evidence of their impact and the value of continued investment in communities to Rio. On topics ranging from HIV prevention access to the future of artificial intelligence in HIV programs, advocates were driving conference discussions to ensure the community agenda was seen, heard and acted upon.
The US fiscal year ended this week amid questions about the billion dollars in Congressionally-appropriated foreign assistance, while new strategies for HIV research at the National Institutes of Health (NIH) and the America First Global Health strategy theoretically move into implementation phases. Also, the Global Fund announced five candidates for its Executive Director, and six candidates were shared as possible leaders of the World Health Organization (WHO), just after the US rejected the UN pandemic preparedness declaration at the end of last week.
There is no shortage of global health news this week. Against the backdrop of the UN General Assembly (UNGA 81), this issue covers efforts to reshape the global health architecture through the Accra Reset, proposed and withdrawn Executive Orders affecting NIH grant making, NIAID restructuring developments, and preparations to expand access to generic lenacapavir for PrEP.
This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for greater transparency around a proposed NIAID restructuring, and a new lawsuit challenging NIH’s screening of research grants. With today as the final day to comment on the NIAID proposal, make your voice heard. And read on for a provocative Lancet commentary on the challenges of trying to reform global health architecture.
showing 1-10 of 1276
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.